Please login to the form below

Not currently logged in
Email:
Password:

Neurocentrx appoints two members to the board

Nigel Brooksby and Dr Tim Corn join the pharma group

Nigel BrooksbyNeurocentrx, a UK-based pharmaceutical company, has appointed Nigel Brooksby (pictured right) as non-executive chairman.

Brooksby brings experience in business and growth strategy across the healthcare sector having held senior global positions at Pfizer, Sanofi and Wellcome - now GSK.

His career history has seen him work in private equity and venture capital and he has been president of the ABPI.

Brooksby said: “My focus is to accelerate the business model and drive commercial clinical trials to raise international awareness of what we are offering, and enter the global market.

“I look forward to working the team, and helping to drive the company to an exciting new stage in their development.”

Joining Brooksby is EUSA Pharma’s former chief medical officer Dr Tim Corn, who becomes the pharma group’s non-executive director.

Carmel Reilly, chief executive officer of Neurocentrx, said: “I am honoured to welcome the extraordinary talents of Nigel and Tim onto the board.

“This is an important milestone for Neurocentrx and marks the start of an exciting new phase of our growth.”

13th April 2018

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
M&F Health

M&F Health is a full service communications agency, dedicated to the health and wellbeing sector. We are an independent amongst...

Latest intelligence

China’s clinical trial shake-up
As many of the obstacles to running clinical trials in China fall away, the country is proving to be a better research location...
Alzheimer’s disease – is Europe prepared if a breakthrough treatment becomes available?
Healthcare leaders in the European Union should begin preparing for a breakthrough now...
The UK’s new five-year pricing agreement
Pharma has agreed to capped growth again - in exchange for uptake promises...

Infographics